Genomic Valley Biotech Ltd

As of June 30, 2026, Genomic Valley Biotech Ltd carries a market capitalization of 88.43M, placing it among publicly traded companies globally. Its enterprise value stands at 88.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Genomic Valley Biotech Ltd has 2.92M shares outstanding.

As of June 30, 2026, Genomic Valley Biotech Ltd trades at a trailing price-to-earnings ratio of 228.28.

As of June 30, 2026, Genomic Valley Biotech Ltd trades at an EV/EBITDA multiple of 160.61 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 41.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 172.20 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 88.43M versus a market cap of 88.43M, with the gap driven by net debt and cash on the balance sheet.

Over the twelve months ended June 30, 2026, Genomic Valley Biotech Ltd recorded 97,369.00 in income tax expense. That works out to an effective tax rate of 18.96, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 513,523.00, leaving 416,154.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Genomic Valley Biotech Ltd's stock has gained approximately 14.83% over the past 52 weeks. The 50-day moving average sits at 30.50, while the 200-day moving average is 27.67.

Over the twelve months ended June 30, 2026, Genomic Valley Biotech Ltd generated 2.16M in revenue and converted that into 416,154.00 in net income, yielding earnings per share of 0.13. EBITDA reached 550,588.00, while operating income came in at 513,524.00.

Over the twelve months ended June 30, 2026, Genomic Valley Biotech Ltd posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 23.83 and net profit margin of 19.31 provide insight into operational efficiency.